Our results indicate the presence of a high percentage (≥70%) of CD133+ cells in the three cancer cell lines analyzed (B16F10 murine melanoma, MCF7 breast cancer and INER51 lung cancer cells) as assessed by immunocytochemistry. This evidence concerns the gene PROM1 and breast cancer.